Table Graph
      published meta-analysis   sensitivity analysis   studies

antiviral and associated therapy in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsFACCT Trial, 2021 0.69 [0.28; 1.68] GS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50] GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86] Krolewiecki, 2020 0.49 [0.01; 26.05] 0.67[0.34; 1.33]FACCT Trial, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Krolewiecki, 202040%1,083moderatenot evaluable deathsdetailed resultsChiCTR2000030054-HCQ (Chen), 2020 0.66 [0.01; 35.52] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.43 [0.13; 1.44] Dabbous HM, 2020 0.51 [0.02; 15.41] FACCT Trial, 2021 0.96 [0.44; 2.08] GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40] GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84] HC-nCoV (Shanghai), 2020 1.00 [0.02; 53.89] Khamis, 2020 0.83 [0.23; 2.96] Krolewiecki, 2020 0.49 [0.01; 26.05] NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25] NCT04542694, 2020 1.00 [0.02; 50.90] Udwadia, 2020 0.50 [0.02; 15.03] 0.77[0.51; 1.17]ChiCTR2000030054-HCQ (Chen), 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, Dabbous HM, 2020, FACCT Trial, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, HC-nCoV (Shanghai), 2020, Khamis, 2020, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Udwadia, 2020140%3,064moderatelow deaths (time to event analysis only)detailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24] GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40] GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84] 0.64[0.28; 1.48]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202030%1,141moderatenot evaluable clinical deteriorationdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.99 [0.57; 1.72] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12] ELACOI (lopinavir/ritonavir), 2020 3.69 [0.37; 36.57] ELACOI (Standard of care), 2020 0.86 [0.06; 11.36] Kamran, 2020 0.95 [0.32; 2.78] Li T, 2020 0.48 [0.01; 27.44] NCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84] Zhaowei Chen, 2020 0.11 [0.01; 2.19] 0.85[0.56; 1.28]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Kamran, 2020, Li T, 2020, NCT04523831 (Mahmud), 2020, Zhaowei Chen, 2020825%1,770moderatenot evaluable clinical improvementdetailed resultsAVIFAVIR, 2020 0.53 [0.13; 2.19] Chachar, 2020 1.19 [0.38; 3.72] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.81 [0.54; 1.22] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43] GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74] GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49] NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38] NCT04542694, 2020 2.10 [1.04; 4.24] Ruzhentsova T, 2020 1.63 [1.14; 2.34] Tang, 2020 1.01 [0.59; 1.74] Udwadia, 2020 1.75 [1.10; 2.79] 1.30[1.04; 1.61]AVIFAVIR, 2020, Chachar, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Ruzhentsova T, 2020, Tang, 2020, Udwadia, 20201145%2,718moderatelow clinical improvement (14-day)detailed resultsAVIFAVIR, 2020 0.53 [0.13; 2.19] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.01 [0.58; 1.76] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43] GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47] GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44] Ruzhentsova T, 2020 1.28 [1.05; 1.56] 1.19[0.97; 1.46]AVIFAVIR, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Ruzhentsova T, 2020728%2,235moderatenot evaluable clinical improvement (21-day)detailed resultsLi T, 2020 2.09 [0.04; 119.96] 2.09[0.04; 119.96]Li T, 202010%18NAnot evaluable clinical improvement (28-day)detailed resultsGS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42] GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17] Ruzhentsova T, 2020 1.11 [0.96; 1.29] Udwadia, 2020 1.75 [1.10; 2.79] 1.47[1.06; 2.04]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Ruzhentsova T, 2020, Udwadia, 2020459%1,102moderatenot evaluable clinical improvement (7-day)detailed resultsChachar, 2020 1.19 [0.38; 3.72] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.89 [0.59; 1.35] GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53] GS-US-540-5774, 5 days, 2020 1.41 [0.94; 2.09] NCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93] NCT04542694, 2020 2.10 [1.04; 4.24] Ruzhentsova T, 2020 1.50 [1.02; 2.21] 1.35[1.07; 1.71]Chachar, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Ruzhentsova T, 2020742%1,896moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsFACCT Trial, 2021 0.85 [0.62; 1.16] GS-US-540-5774, 10 days, 2020 1.16 [0.94; 1.44] GS-US-540-5774, 5 days, 2020 1.15 [0.93; 1.42] NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38] Ruzhentsova T, 2020 1.63 [1.14; 2.34] Tang, 2020 1.01 [0.59; 1.74] Udwadia, 2020 1.75 [1.10; 2.79] 1.24[1.02; 1.50]FACCT Trial, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NCT04523831 (Mahmud), 2020, Ruzhentsova T, 2020, Tang, 2020, Udwadia, 2020754%1,887moderatenot evaluable hospital dischargedetailed resultsFACCT Trial, 2021 0.88 [0.64; 1.21] Li T, 2020 10.00 [1.03; 97.50] Udwadia, 2020 1.41 [0.97; 2.03] 1.26[0.70; 2.25]FACCT Trial, 2021, Li T, 2020, Udwadia, 2020372%422moderatenot evaluable mechanical ventilationdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.77 [0.81; 3.87] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.54 [0.70; 3.37] GS-US-540-5774, 10 days, 2020 0.26 [0.03; 2.30] GS-US-540-5774, 5 days, 2020 0.13 [0.01; 2.45] Li T, 2020 0.40 [0.04; 3.90] Udwadia, 2020 0.06 [0.01; 0.83] 0.65[0.25; 1.69]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Li T, 2020, Udwadia, 2020656%1,492moderateserious mechanical ventilation (time to event analysis only)detailed resultsUdwadia, 2020 0.06 [0.01; 0.83] 0.06[0.01; 0.83]Udwadia, 202010%14NAnot evaluable radiologic improvement (14-day)detailed resultsELACOI (lopinavir/ritonavir), 2020 0.48 [0.02; 11.28] ELACOI (Standard of care), 2020 0.18 [0.01; 3.99] Rashad A (AZI vs SoC), 2021 1.64 [0.94; 2.88] 1.17[0.42; 3.26]ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Rashad A (AZI vs SoC), 2021316%252moderatenot evaluable radiologic improvement (7-day)detailed resultsELACOI (lopinavir/ritonavir), 2020 0.10 [0.00; 2.09] ELACOI (Standard of care), 2020 0.08 [0.00; 1.71] Zhaowei Chen, 2020 3.43 [1.10; 10.70] 0.40[0.02; 6.97]ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Zhaowei Chen, 2020377%108moderatenot evaluable viral clearance detailed resultsAVIFAVIR, 2020 3.89 [1.23; 12.29] Dabbous HM, 2020 1.33 [0.60; 2.93] ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76] ELACOI (Standard of care), 2020 2.80 [0.31; 25.53] HC-nCoV (Shanghai), 2020 0.46 [0.04; 5.75] NCT04542694, 2020 13.03 [2.96; 57.24] Ruzhentsova T, 2020 1.28 [0.92; 1.79] Tang, 2020 0.85 [0.58; 1.23] Udwadia, 2020 1.37 [0.94; 1.98] 1.48[1.00; 2.17]AVIFAVIR, 2020, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, HC-nCoV (Shanghai), 2020, NCT04542694, 2020, Ruzhentsova T, 2020, Tang, 2020, Udwadia, 2020958%908moderatenot evaluable viral clearance (time to event analysis only)detailed resultsRuzhentsova T, 2020 1.28 [0.92; 1.79] Tang, 2020 0.85 [0.58; 1.23] Udwadia, 2020 1.37 [0.94; 1.98] 1.15[0.86; 1.53]Ruzhentsova T, 2020, Tang, 2020, Udwadia, 2020347%468moderatenot evaluable viral clearance by day 14detailed resultsAVIFAVIR, 2020 3.08 [0.62; 15.39] Bukhari, 2021 0.91 [0.02; 46.94] ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76] ELACOI (Standard of care), 2020 2.80 [0.31; 25.53] Li T, 2020 1.00 [0.03; 34.67] Ruzhentsova T, 2020 0.99 [0.93; 1.06] 0.99[0.93; 1.06]AVIFAVIR, 2020, Bukhari, 2021, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Li T, 2020, Ruzhentsova T, 202060%383moderatenot evaluable viral clearance by day 7detailed resultsAVIFAVIR, 2020 3.89 [1.23; 12.29] Bukhari, 2021 11.56 [3.53; 37.91] Dabbous HM, 2020 1.33 [0.60; 2.93] ELACOI (lopinavir/ritonavir), 2020 0.30 [0.05; 1.91] ELACOI (Standard of care), 2020 0.67 [0.10; 4.58] Ruzhentsova T, 2020 1.05 [0.92; 1.20] 1.69[0.76; 3.78]AVIFAVIR, 2020, Bukhari, 2021, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Ruzhentsova T, 2020678%464moderatenot evaluable ICU admissiondetailed resultsFACCT Trial, 2021 1.42 [0.79; 2.55] Khamis, 2020 1.03 [0.35; 3.03] 1.32[0.79; 2.21]FACCT Trial, 2021, Khamis, 202020%343moderatenot evaluable recoverydetailed resultsGS-US-540-5774, 10 days, 2020 1.11 [0.90; 1.37] GS-US-540-5774, 5 days, 2020 1.18 [0.96; 1.45] 1.15[0.99; 1.33]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202020%796moderatenot evaluable serious adverse eventsdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.87 [0.36; 9.75] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.02 [0.20; 5.10] GS-US-540-5774, 10 days, 2020 0.55 [0.25; 1.23] GS-US-540-5774, 5 days, 2020 0.50 [0.22; 1.14] Krolewiecki, 2020 1.00 [0.03; 31.59] NCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58] NCT04542694, 2020 6.15 [0.30; 124.49] Ruzhentsova T, 2020 2.06 [0.09; 46.40] Udwadia, 2020 1.03 [0.02; 52.48] 0.74[0.45; 1.20]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Ruzhentsova T, 2020, Udwadia, 202090%2,557moderateserious acute kidney injury detailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.18 [0.44; 3.18] 1.18[0.44; 3.18]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%345NAnot evaluable adverse eventsdetailed resultsChiCTR2000030054-HCQ (Chen), 2020 5.00 [0.85; 29.57] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.22 [1.43; 3.44] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.21 [0.82; 1.78] GS-US-540-5774, 10 days, 2020 1.63 [1.09; 2.42] GS-US-540-5774, 5 days, 2020 1.21 [0.82; 1.80] HC-nCoV (Shanghai), 2020 1.45 [0.26; 8.01] Krolewiecki, 2020 1.53 [0.42; 5.58] NCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77] NCT04542694, 2020 1.00 [0.54; 1.85] Ruzhentsova T, 2020 1.90 [0.96; 3.80] Udwadia, 2020 6.36 [2.43; 16.65] 1.65[1.24; 2.20]ChiCTR2000030054-HCQ (Chen), 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, HC-nCoV (Shanghai), 2020, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Ruzhentsova T, 2020, Udwadia, 20201250%2,949moderatelow arrhythmiadetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.24 [0.23; 21.69] 2.24[0.23; 21.69]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%416NAnot evaluable elevated liver enzymesdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 3.48 [1.40; 8.64] 3.48[1.40; 8.64]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%416NAnot evaluable long QTdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 9.79 [1.27; 75.50] 9.79[1.27; 75.50]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%174NAnot evaluable renal impairmentdetailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.35 [0.47; 3.86] 1.35[0.47; 3.86]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 202010%331NAnot evaluable Thromboembolic eventsdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.89 [0.31; 2.55] 0.89[0.31; 2.55]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%345NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-05-04 08:59 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons